# Post-transplantation Cyclophosphamide for Haploidentical Transplant From Maternal or Collateral Donors

> **NCT02412423** · PHASE4 · COMPLETED · sponsor: **Peking University People's Hospital** · enrollment: 30 (actual)

## Conditions studied

- Hematopoietic Stem Cell Transplantation

## Interventions

- **DRUG:** post-transplantation cyclophosphamide

## Key facts

- **NCT ID:** NCT02412423
- **Lead sponsor:** Peking University People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03
- **Primary completion:** 2016-08
- **Final completion:** 2017-03
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2020-09-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02412423

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02412423, "Post-transplantation Cyclophosphamide for Haploidentical Transplant From Maternal or Collateral Donors". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02412423. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*